Codegate is an open-source security gateway and multiplexing framework for AI agentic systems. Developed by Stacklok, it provides secure workspaces and policy-based access control, enabling developers to build and manage complex multi-agent applications safely and efficiently.
DrugCard is an AI-powered data intelligence platform designed for pharmacovigilance. It automates the process of local medical literature screening, helping pharmaceutical companies, CROs, and freelancers ensure drug safety and regulatory compliance efficiently across multiple languages and regions.
Codegate is an open-source security gateway and multiplexing framework for AI agentic systems. Developed by Stacklok, it provides secure workspaces and policy-based access control, enabling developers to build and manage complex multi-agent applications safely and efficiently.
DrugCard is an AI-powered data intelligence platform designed for pharmacovigilance. It automates the process of local medical literature screening, helping pharmaceutical companies, CROs, and freelancers ensure drug safety and regulatory compliance efficiently across multiple languages and regions.
| Feature | codegate | DrugCard |
|---|---|---|
| Primary category | Agentic Frameworks | Pharmacovigilance |
| Added | 2025-08-16 | 2025-08-10 |
| Pricing | Free | Paid |
| Official website | github.com | drug-card.io |
| Product type | App | Website |
| Performance data | ||
| User rating | Not verified | Not verified |
| Comments | 0 | 0 |
| Monthly visits | 636.1M | 5.6K |
| Monthly growth | 0.8% | 51.1% |
| Favorites | 108 | 132 |
| Details | View details | View details |
Compare codegate and DrugCard by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
In the codegate vs DrugCard monthly traffic comparison, codegate currently shows 636.1M visits and DrugCard shows 5.6K; codegate has about 113,971.7 times the visible traffic of DrugCard, an absolute difference of about 636.1M visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
codegate is registered at the github.com/stacklok subpage. Because the current data does not state whether other host pages are excluded, treat this as domain-level context rather than independent traffic for one product or project.
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 36.14% | 229.9M |
| 🇨🇳China | 22.96% | 146M |
| 🇮🇳India | 17.41% | 110.7M |
| 🇷🇺Russia | 15.84% | 100.8M |
| 🇩🇪Germany | 7.65% | 48.7M |
| Source type | Percentage | Traffic |
|---|---|---|
| Direct | 82.14% | 522.5M |
| Referral | 16.14% | 102.7M |
| 1.72% | 10.9M |
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 69.05% | 3.9K |
| 🇮🇳India | 17.3% | 966 |
| 🇭🇺Hungary | 8.29% | 463 |
| 🇵🇱Poland | 3.6% | 201 |
| 🇮🇪Ireland | 1.76% | 98 |
This in-depth codegate vs DrugCard comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. codegate is primarily listed under “Agentic Frameworks”, while DrugCard is primarily listed under “Pharmacovigilance”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (codegate: Agentic Frameworks; DrugCard: Pharmacovigilance); Product type (codegate: App; DrugCard: Website); Pricing (codegate: Free; DrugCard: Paid); Monthly visits (codegate: 636.1M; DrugCard: 5.6K); Monthly growth (codegate: 0.8%; DrugCard: 51.1%). These facts are more useful for selection than brand visibility alone.
In the codegate vs DrugCard monthly traffic comparison, codegate currently shows 636.1M visits and DrugCard shows 5.6K; codegate has about 113,971.7 times the visible traffic of DrugCard, an absolute difference of about 636.1M visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
codegate is registered at the github.com/stacklok subpage. Because the current data does not state whether other host pages are excluded, treat this as domain-level context rather than independent traffic for one product or project.
codegate is registered under a github.com subpath, so its large visible total may include the host platform. The current data does not justify choosing codegate for traffic alone; shortlist by unique taxonomy and use case, then validate with the same tasks.
codegate and DrugCard currently overlap in shared categories: Automation; shared tags: automation. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
codegate's unique categories/tags are Agentic Frameworks, Security, agentic framework, AI agent, AI security, developer tools, DevSecOps, and kubernetes; DrugCard's are Pharmacovigilance, AI for pharma, CRO tools, data intelligence, drug safety, healthcare AI, medical literature screening, and pharmacovigilance. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
codegate has no verified rating, 0 comments, 108 favorites, and 111 likes；DrugCard has no verified rating, 0 comments, 132 favorites, and 138 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Put codegate on the priority trial list when the task aligns with “Agentic Frameworks” and especially Agentic Frameworks, Security, agentic framework, AI agent, AI security, and developer tools. This follows recorded positioning and does not imply unlisted capabilities are absent.
codegate also currently records: pricing is free, product type is app, 636.1M monthly visits shown for the registered host (subpage scope unknown), no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
Put DrugCard on the priority trial list when the task aligns with “Pharmacovigilance” and especially Pharmacovigilance, AI for pharma, CRO tools, data intelligence, drug safety, and healthcare AI. This follows recorded positioning and does not imply unlisted capabilities are absent.
DrugCard also currently records: pricing is paid, product type is website, 5.6K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in codegate and DrugCard, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.
